Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy

NCT04692688 is registered in ClinicalTrials.gov with Ocuphire Pharma, Inc. as lead sponsor.

NCT NCT04692688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04692688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
Lead sponsor
Ocuphire Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2021
Completion date
January 25, 2023
Enrollment
103 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, diabetic retinopathy, npdr - non proliferative diabetic retinopathy, pdr - proliferative diabetic retinopathy